Robert Panvini, MD
Pediatric Urology · San Jose, CANPI 1346313210
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,531 of the $9,446 with a category attached, or 69.1%. It is spread thinly across 37 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2023 at $2,644 and has fallen 97.9% since, to $56 in 2025. Among pediatric urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$2K
- Johnson & Johnson$1K
- Bayer$1K
- Sumitomo Pharma America, Inc.$643
- Amgen$512
- Teleflex LLC$434
- plus $3K from 31 others
What the payments were for
- Consulting fees$1,54616%
- Travel & lodging$4044%
- Food & beverage$6,53169%
- Education$96610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 84 | $2,080 |
| Johnson & Johnson(2 entities) | 33 | $1,452 |
| Bayer | 14 | $1,146 |
| Sumitomo Pharma America, Inc. | 23 | $643 |
| Amgen | 20 | $512 |
| Teleflex LLC | 2 | $434 |
| AbbVie(2 entities) | 21 | $419 |
| Antares Pharma, Inc. | 14 | $307 |
| Dendreon Pharmaceuticals LLC | 10 | $291 |
| Coloplast | 14 | $285 |
| Urovant Sciences Inc | 9 | $274 |
| 180 Medical, Inc. | 13 | $256 |
| Pfizer | 20 | $247 |
| AstraZeneca | 6 | $113 |
| Zyla Life Sciences, Inc. | 6 | $109 |
| Accord Healthcare, Inc. | 5 | $102 |
| Endo Pharmaceuticals Inc. | 4 | $84 |
| Tolmar Pharmaceuticals, Inc. | 4 | $77 |
| Myriad Genetic Laboratories, Inc. | 3 | $72 |
| Progenics Pharmaceuticals, Inc. | 3 | $69 |
| Immunitybio, Inc. | 2 | $63 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Tolmar, Inc. | 2 | $41 |
| Dentsply IH Inc. | 2 | $39 |
| Photocure Inc | 2 | $34 |
| Clarus Therapeutics Inc. | 2 | $33 |
| Myovant Sciences Inc. | 2 | $27 |
| Foundation Medicine, Inc. | 1 | $24 |
| Assertio Therapeutics, Inc. | 2 | $24 |
| Neotract Inc. | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $21 |
| Procept Biorobotics Corporation | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Hollister Incorporated | 1 | $19 |
| Axonics, Inc. | 1 | $17 |
| Blue Earth Diagnostics | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,446 in reported general payments places this provider in the 95th percentile of 39 pediatric urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 38 | $539,144 |
| NubeqaDarolutamide | 17 | $224,124 |
| OrgovyxRelugolix | 40 | $109,029 |
| MyrbetriqMirabegron | 58 | $64,177 |
| GemtesaVibegron | 48 | $54,477 |
| Mirabegron ErMirabegron | 15 | $13,364 |
| Tamsulosin Hcl | 537 | $11,234 |
| Finasteride | 321 | $5,952 |
| Oxybutynin Chloride ErOxybutynin Chloride | 138 | $5,558 |
| Dutasteride | 77 | $4,325 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 100 | $2,221 |
| Potassium Citrate ErPotassium Citrate | 15 | $2,045 |
| Testosterone Cypionate | 32 | $1,688 |
| Bethanechol Chloride | 12 | $1,049 |
| Testosterone | 13 | $693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $2,080 | $603,32196 claims |
| BayerNubeqa | $1,146 | $224,12417 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $643 | $163,50788 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 pediatric urology providers in California.
Other pediatric urology in San Jose
- David NudellSan Jose$10K
- Antoine KhouryOrange$9K
- Chi LeeBerkeley$7K
- Sung ChoeWest Covina$6K
- Michael BishaiPasadena$5K
- Alireza AlamLong Beach$5K
- Babak BamshadLos Angeles$4K
- Michael ScottLynwood$2K
- Joel PiserBerkeley$1K
- Elias WehbiOrange$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.